Sun Pharma Inds.
Ticker >

Sun Pharma Inds. share price

Sun Pharmaceutical Industries Ltd.

NSE: SUNPHARMA BSE: 524715 SECTOR: Pharmaceuticals & Drugs  313k   2k   450

1239.30
-1.05 (-0.08%)
NSE: 07 Dec 03:58 PM

Price Summary

Today's High

₹ 1241.9

Today's Low

₹ 1228.9

52 Week High

₹ 1258

52 Week Low

₹ 922.45

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 297349.58 Cr.

Enterprise Value

₹ 304520.97 Cr.

No. of Shares

239.93 Cr.

P/E

404.46

P/B

12.37

Face Value

₹ 1

Div. Yield

0.93 %

Book Value (TTM)

₹  100.23

CASH

₹ 421.28 Cr.

DEBT

₹ 7592.67 Cr.

Promoter Holding

54.48 %

EPS (TTM)

₹  3.06

Sales Growth

33.53%

ROE

7 %

ROCE

7.28%

Profit Growth

1790.89 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Sun Pharmaceutical Industries Ltd.

Molxvir Gloeye Prazopress Pantocid Predmet Garlic Pearls REVITAL VOLINI PEPFIZ Diamox Deslor Cepodem Colvac Livcare Montek Mox CV Nexito

Index Presence

The company is present in 36 Indices.

NIFTY100WEIGHT

Nifty100 Equal Weight
25868.65
  157 (0.610618134638474%)

NIFTYEQWGT

NIFTY50 Equal Weight
25600.3
  5.05078125 (0.019733275705458%)

NFTALLO30

NIFTY Alpha Low-Volatility 30
22297.65
  17.599609375 (0.0789926807070351%)

NIFTY100

Nifty 100
21076.35
  2.19921875 (0.0104356223583624%)

NIFTY

Nifty 50
20901.15
  -36.548828125 (-0.174559906239702%)

NIFTYLOWVOL

Nifty Low Volatility 50
19842.56
  112.490000000002 (0.570144961472518%)

NIFTY500

Nifty 500
18703.85
  23.849609375 (0.127674568388647%)

NT100LOW30

Nifty100 Low Volatility 30
16373
  35.5 (0.217291507268547%)

NIFTYPHARMA

Nifty Pharma
16294.2
  124.650390625 (0.770895863710841%)

NT100ALP30

NIFTY100 Alpha 30
13961.91
  174 (1.26197516519908%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
12861.4
  28.25 (0.220133008186663%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
12857.7
  36.4501953125 (0.284295176464844%)

NIFTY200

Nifty 200
11348.45
  11.25 (0.0992308489414562%)

NIFTYMFG

Nifty Manufacturing
10567.7
  34.900390625 (0.33134960572847%)

NIFTYTOTALMCAP

Nifty Total Market index
10505.45
  12.7001953125 (0.121037814800706%)

NI15

NI15
10359.25
  -18.0498046875 (-0.17393546517126%)

NIFTYHEALTH

Nifty Healthcare Index
10338.65
  72.80078125 (0.709154955703983%)

NIFTY100ESG

NIFTY100 ESG
4039.95
  12.89990234375 (0.320331314171374%)

SENSEX

S&P Bse Sensex
69521.69
  -132.039999999994 (-0.189566301761579%)

BSE HC

S&P Bse Healthcare
30511.77
  158.200000000001 (0.521190752850487%)

BSE500

S&P Bse 500
29584.41
  44.25 (0.149796074225739%)

SNSX50

S&P Bse Sensex50
21893.92
  -30 (-0.136836843046317%)

BSE100

S&P Bse 100
21533.83
  2.7300000000032 (0.0126793336151065%)

BSE200

S&P Bse 200
9279.87
  11.5 (0.124077912297427%)

LMI250

S&P Bse 250 LargeMidCap
8800.19
  11.8000000000011 (0.134268051372333%)

S&P LARGEMIDCAP

S&P Bse Large MidCap
8723.68
  46.5 (0.535888387701999%)

ALLCAP

S&P Bse Allcap
8607.05
  13.4200000000001 (0.156162180591912%)

SHA500

S&P Bse 500 Shariah
8202.93
  35.2700000000004 (0.431825026996724%)

LRGCAP

S&P Bse LargeCap
8018.4
  1.71999999999935 (0.0214552657708644%)

BSE100LARGECAPTMC

S&P Bse 100 LargeCap TMC
7672.07
  5.42999999999938 (0.0708263333089709%)

GREENEX

S&P Bse Greenex
5652.68
  5.11999999999989 (0.0906586207140681%)

CARBONEX

S&P Bse Carbonex
3507.47
  -0.75 (-0.021378362816471%)

SPBSLVIP

S&P Bse Low Volatility
1510.77
  3.70000000000005 (0.245509498563434%)

MFG

S&P Bse Manufacturing
875.97
  -2.26999999999998 (-0.258471488431411%)

S&PDIVSTABLE

S&P Bse Dividend Stability
806.84
  2.75999999999999 (0.343249427917613%)

ESG100

S&P Bse 100 ESG Index
341.01
  -0.100000000000023 (-0.029316056404094%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year33.53%
3 Year18.42%
5 Year18.3%

Profit Growth

1 Year1790.89%
3 Year-19.25%
5 Year40.79%

ROE%

1 Year7%
3 Year3.3%
5 Year5.42%

ROCE %

1 Year7.28%
3 Year4.31%
5 Year5.89%

Debt/Equity

0.3197

Price to Cash Flow

586.4

Interest Cover Ratio

4.68725909610742

CFO/PAT (5 Yr. Avg.)

1.59033690509173

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2023 54.48 2.44
Jun 2023 54.48 2.29
Mar 2023 54.48 1.78
Dec 2022 54.48 1.92
Sep 2022 54.48 2.53
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 18.4219455384214% for the Past 3 years.
  • Company’s PEG ratio is 0.225818904973348.
  • The company has an efficient Cash Conversion Cycle of -18.6467010455568 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.59033690509173.
  • The company has a high promoter holding of 54.48%.

 Limitations

  • The company has shown a poor profit growth of -19.2509385495058% for the Past 3 years.
  • Company has a poor ROE of 3.29651051069589% over the past 3 years.
  • Company has a poor ROCE of 4.31020370520073% over the past 3 years
  • Tax rate is low at 2.89078429683237.
  • The company is trading at a high PE of 404.46.
  • The company is trading at a high EV/EBITDA of 49.9689.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023
Net Sales 5285.29 4645.75 5948.22 4466.07 5096.21
Total Expenditure 3622.12 3652.97 3587.57 3517.31 3719.28
Operating Profit 1663.17 992.78 2360.65 948.76 1376.93
Other Income 41.71 74.63 120.3 163.54 115.93
Interest 92.77 130.89 161.45 157.94 193.63
Depreciation 383.95 430.44 411.98 415.27 392.71
Exceptional Items 0 0 -2937.79 -149.21 0
Profit Before Tax 1228.16 506.08 -1030.27 389.88 906.52
Tax 15.15 19.35 -9.45 9.24 17.89
Profit After Tax 1213.01 486.73 -1020.82 380.64 888.63
Adjusted EPS (Rs) 5.06 2.03 -4.25 1.59 3.7

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 10303.21 12531.93 14116.05 15585.98 20812.14
Total Expenditure 8561.66 9820.28 11859.04 12917.42 14389.54
Operating Profit 1741.55 2711.65 2257.01 2668.56 6422.6
Other Income 1286.15 1510.92 192.07 1196.88 329.29
Interest 540.92 408.01 267.52 388.1 472.18
Depreciation 552.95 561.56 1236.43 1349.95 1600.87
Exceptional Items -1214.38 0 -89.56 -1820.53 -2937.79
Profit Before Tax 719.45 3253 855.57 306.86 1741.05
Tax -97.15 41.86 13.17 406.85 50.33
Net Profit 816.6 3211.14 842.4 -99.99 1690.72
Adjusted EPS (Rs.) 3.4 13.38 3.51 -0.42 7.05

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 239.93 239.93 239.93 239.93 239.93
Total Reserves 22603.68 24156.29 26698.54 24348.02 23508.43
Borrowings 1422.5 1256.69 5300.02 4865.64 7586.73
Other N/C liabilities 514.09 1890.56 1928.04 1498.21 1642.04
Current liabilities 13271.83 11203.74 9951.33 10105.83 8365.44
Total Liabilities 38052.03 38747.21 44117.86 41057.63 41343.19
Assets
Net Block 4978.42 5228.74 9668.79 9712.78 8711.67
Capital WIP 456.25 384.35 459.2 358.94 328.87
Intangible WIP 186.29 212.26 631.18 469.7 524.04
Investments 17656.16 16966.65 15506.2 15355.83 12416.14
Loans & Advances 3592.57 4013.14 5120.85 5451.94 2882.26
Other N/C Assets 12.57 0.95 1.56 4.69 36.46
Current Assets 11169.77 11941.12 12730.08 9703.75 16443.75
Total Assets 38052.03 38747.21 44117.86 41057.63 41343.19
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 719.45 3253 855.57 306.86 1741.05
Adjustment 448.66 -217.09 1717.87 1266.29 4823.4
Changes in Assets & Liabilities 111.5 -1393 -2752.28 3903.67 -5625.38
Tax Paid -37.43 -337.06 -237.67 2159.54 -431.99
Operating Cash Flow 1242.18 1305.85 -416.51 7636.36 507.08
Investing Cash Flow 431.37 1483.04 1452.47 -2697.04 -685.64
Financing Cash Flow -1468.59 -2871.15 -999.73 -4870.85 169.31
Net Cash Flow 204.96 -82.26 36.23 68.47 -9.25

Corporate Actions

Investors Details

PARTICULARS Sep 2022% Dec 2022% Mar 2023% Jun 2023% Sep 2023%
promoters 54.48 54.48 54.48 54.48 54.48
aalok dilip shanghvi 0.12 0.12 0.12 0.12 0.12
aditya medisales limited 1.67 1.67 1.67 1.67 1.67
dilip shantilal shanghvi - - - - 9.60
kumud shantilal shanghvi 0.01 0.01 0.01 0.01 0.01
raksha s.valia 1.20 1.20 1.20 - 1.20
shanghvi family & friends... 0.05 0.05 0.05 0.05 0.05
shanghvi finance private ... 40.30 40.30 40.30 40.30 40.30
sudhir vrundavan valia - - - - 0.60
unimed investments limite... 0.43 0.43 0.43 0.43 0.43
vibha dilip shanghvi 0.37 0.37 0.37 0.37 0.37
vidhi dilip shanghvi 0.12 0.12 0.12 0.12 0.12
dilip shanghvi - - - 9.60 -
raksha valia - - - 1.20 -
sudhir valia - - - 0.60 -
dilip.s.shanghvi 9.60 9.60 9.60 - -
sudhir v. valia 0.60 0.60 0.60 - -
PARTICULARS Sep 2022% Dec 2022% Mar 2023% Jun 2023% Sep 2023%
investors 45.52 45.52 45.52 45.52 45.52
government of singapore - 1.02 - - 1.20
government pension fund g... 1.09 1.14 1.08 1.15 1.03
icici prudential value di... 2.80 3.02 3.06 - 3.44
investor education and pr... 0.08 - 0.10 0.10 0.10
life insurance corporatio... 4.38 3.64 3.28 3.11 2.91
llp 0.26 0.25 0.25 0.25 0.20
nps trust- a/c sbi pensio... - - - 1.07 1.13
sbi nifty 50 etf 2.44 2.48 2.52 - 2.38
icici mutual funds - - - 3.37 -
sbi funds - - - 2.47 -
investor education and pr... - 0.10 - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Sun Pharmaceutical Industries informs about disclosure 6 Dec 2023, 9:42AM Sun Pharma’s arm enters into licensing agreement with Aclaris Therapeutics, Inc.6 Dec 2023, 9:19AM Sun Pharmaceutical Industries reports 6% rise in Q2 consolidated net profit1 Nov 2023, 2:22PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharma Inds. - Quaterly Results1 Nov 2023, 1:23PM Sun Pharmaceutical Industries informs about press release 30 Oct 2023, 4:46PM Sun Pharma inks licensing agreement with Zydus Lifesciences for co-marketing of Desidustat30 Oct 2023, 11:08AM Sun Pharma’s arm recalls 144 bottles of anti-depression drug from US market20 Oct 2023, 12:00PM Sun Pharmaceutical Industries submits analyst meet intimation17 Oct 2023, 4:29PM Sun Pharmaceutical Industries informs about press release16 Oct 2023, 1:05PM Sun Pharma’s arm recalling 69,707 cartons of Cequa from US market9 Oct 2023, 12:40PM Sun Pharmaceutical Industries informs about press release6 Oct 2023, 10:12AM Sun Pharmaceutical Industries to acquire around 37.76% stake in EzeRx6 Oct 2023, 10:11AM Sun Pharma’s arm to acquire balance 25% outstanding shares in Sun Pharma de Mexico29 Sep 2023, 11:42AM Sun Pharma’s arm launches WINLEVI in Canada27 Sep 2023, 3:08PM Sun Pharmaceutical Industries informs about loss of share certificates25 Sep 2023, 5:27PM Sun Pharmaceutical Industries informs about loss of share certificates21 Sep 2023, 5:23PM Sun Pharmaceutical Industries informs about press release14 Sep 2023, 12:25PM Sun Pharmaceutical’s arm enters into license agreement with Pharmazz Inc14 Sep 2023, 11:40AM Sun Pharma aiming to spend 7-8% of sales on R&D in current fiscal29 Aug 2023, 11:27AM Sun Pharmaceutical Industries informs about loss of share certificate 19 Aug 2023, 10:05AM Sun Pharmaceutical Industries informs about analyst meet16 Aug 2023, 2:40PM Sun Pharmaceutical Industries informs about press release3 Aug 2023, 3:43PM Sun Pharmaceutical Industries reports marginal fall in Q1 consolidated net profit3 Aug 2023, 2:28PM Sun Pharma Inds. - Quaterly Results3 Aug 2023, 2:05PM Sun Pharma Inds. - Quaterly Results3 Aug 2023, 2:05PM Sun Pharma Inds. - Quaterly Results3 Aug 2023, 2:05PM Sun Pharma eyeing at high single-digit growth in consolidated topline in FY2431 Jul 2023, 3:09PM Sun Pharmaceutical Industries submits clarification note to BRSR31 Jul 2023, 2:49PM Sun Pharmaceutical Industries informs about disclosure 20 Jul 2023, 5:01PM Sun Pharmaceutical Industries informs about press release13 Jul 2023, 2:37PM Sun Pharmaceutical Industries informs about disclosure 4 Jul 2023, 10:44AM Sun Pharmaceutical Industries informs about closure of trading window 28 Jun 2023, 10:23AM Sun Pharmaceutical Industries informs about loss of share certificates21 Jun 2023, 10:25AM Sun Pharmaceutical Industries’ arm gets Health Canada’s nod for WINLEVI20 Jun 2023, 10:22AM Sun Pharmaceutical Industries informs about loss of share certificates7 Jun 2023, 4:56PM Sun Pharma gets approval from China NMPA for NDA of tildrakizumab injection31 May 2023, 12:30PM Sun Pharmaceutical Industries enters into licensing agreement with Philogen30 May 2023, 12:00PM Sun Pharmaceutical planning to acquire Israel-based Taro Pharmaceutical Industries29 May 2023, 11:01AM Sun Pharmaceutical Industries informs about update 27 May 2023, 10:27AM Sun Pharmaceutical Industries informs about disclosure 27 May 2023, 10:25AM Sun Pharmaceutical Industries reports consolidated net profit of Rs 1984.47 crore in Q4 26 May 2023, 5:17PM Sun Pharma Inds. - Quaterly Results26 May 2023, 2:47PM Sun Pharma Inds. - Quaterly Results26 May 2023, 2:47PM Sun Pharma Inds. - Quaterly Results26 May 2023, 2:47PM Sun Pharma recalls pre-filled syringes of Fyremadel injection in US market8 May 2023, 9:40AM Sun Pharmaceutical launches novel ophthalmology treatment CEQUA in India25 Apr 2023, 2:50PM Sun Pharmaceutical Industries’ US-based arm recalls generic drug in US market24 Apr 2023, 10:38AM Sun Pharma inks pact to acquire 60% stake in Vivaldis Health and Foods25 Mar 2023, 11:02AM

Sun Pharma Inds. Stock Price Analysis and Quick Research Report. Is Sun Pharma Inds. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Sun Pharma Inds. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Sun Pharma Inds. cash from the operating activity was Rs 507.08 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Sun Pharma Inds. has a Debt to Equity ratio of 0.3197 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Sun Pharma Inds. , the EPS growth was 1791.07271418287 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Sun Pharma Inds. has OPM of 30.8598731317395 % which is a good sign for profitability.
     
  • ROE: Sun Pharma Inds. have a poor ROE of 6.99565192295399 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Sun Pharma Inds. is Rs 1239.3. One can use valuation calculators of ticker to know if Sun Pharma Inds. share price is undervalued or overvalued.
Last Updated on:
Brief about Sun Pharma Inds.

Sun Pharmaceutical Industries Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

Sun Pharmaceutical Industries Ltd. is a leading pharmaceutical company in India, providing a wide range of products and services to its customers. In this article, we will analyze Sun Pharmaceutical Industries Ltd. from a stock market perspective. We will cover various topics such as share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news, concall, transcripts, investor presentations, promoters, and shareholders.

Sun Pharmaceutical Industries Ltd. Share Price:

The share price of Sun Pharmaceutical Industries Ltd. is an important indicator of investor sentiment towards the company. The share price is influenced by various factors such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s share price and identify any trends or patterns. Sun Pharmaceutical Industries Ltd.'s share price has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. Balance Sheet:

Sun Pharmaceutical Industries Ltd.'s balance sheet provides crucial information about its financial health. The company's assets include fixed assets, investments, and other assets. Liabilities include borrowings, trade payables, and other liabilities. Equity includes share capital, reserves, and surplus. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s balance sheet and identify any red flags. The company's balance sheet has remained strong over the years, with a healthy mix of assets and liabilities.

Sun Pharmaceutical Industries Ltd. Annual Report:

Sun Pharmaceutical Industries Ltd. releases an annual report every year, which provides detailed information about the company's financial performance, strategic initiatives, and future plans. The annual report includes a letter from the Chairman, financial statements, and management discussion and analysis. Investors can download Sun Pharmaceutical Industries Ltd.'s annual report from our website and use it to make informed investment decisions. The annual report provides valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Dividend:

Sun Pharmaceutical Industries Ltd. pays dividends to its shareholders on a regular basis. Dividends are a portion of the company's profits that are distributed to shareholders. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s dividend history and dividend yield. The company has a consistent track record of paying dividends to its shareholders, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Quarterly Results:

Sun Pharmaceutical Industries Ltd. releases its quarterly results every three months. The quarterly results provide information about the company's revenue, earnings, and expenses. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s quarterly results and identify any trends or patterns. The quarterly results are an important indicator of the company's financial health and performance.

Sun Pharmaceutical Industries Ltd. Stock Price:

Sun Pharmaceutical Industries Ltd.'s stock price is affected by various factors such as the company's financial performance, global economic conditions, and market sentiment. Investors can use our pre-built screening tools to track Sun Pharmaceutical Industries Ltd.'s stock price and identify potential buying opportunities. The stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. Price Chart:

A price chart provides a visual representation of a company's stock price over a period of time. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s price chart and identify any trends or patterns. The price chart shows that the stock price of Sun Pharmaceutical Industries Ltd. has been on an upward trend over the past few years, reflecting the company's strong financial performance and growth prospects.

Sun Pharmaceutical Industries Ltd. News:

Keeping up to date with the latest news about Sun Pharmaceutical Industries Ltd. is important for investors. Our website provides the latest news about Sun Pharmaceutical Industries Ltd. from various sources such as financial news websites and social media. Investors can use this information to make informed investment decisions.

Sun Pharmaceutical Industries Ltd. Concall:

Sun Pharmaceutical Industries Ltd. holds conference calls with analysts and investors to discuss its financial performance and future plans. Investors can listen to Sun Pharmaceutical Industries Ltd.'s concall and use the information provided to make informed investment decisions. Our website provides information about upcoming concalls and links to listen to past concalls.

Sun Pharmaceutical Industries Ltd. Transcripts:

Transcripts of Sun Pharmaceutical Industries Ltd.'s concalls are available on our website. Investors can download the transcripts and use them to analyze the company's financial performance and future plans. The transcripts provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Investor Presentations:

Sun Pharmaceutical Industries Ltd. provides investor presentations on its website. These presentations provide information about the company's financial performance, strategic initiatives, and future plans. Investors can download Sun Pharmaceutical Industries Ltd.'s investor presentations from our website and use them to make informed investment decisions. The investor presentations provide valuable insights into the company's operations and financial performance.

Sun Pharmaceutical Industries Ltd. Promoters:

Promoters are individuals or entities that have a significant stake in a company. Sun Pharmaceutical Industries Ltd.'s promoters include various entities that hold a significant stake in the company. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s promoter holdings and identify any potential conflicts of interest. The promoter holdings of Sun Pharmaceutical Industries Ltd. are relatively stable, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Shareholders:

Sun Pharmaceutical Industries Ltd. has a large number of shareholders, including institutional investors and individual investors. Investors can use our pre-built screening tools to analyze Sun Pharmaceutical Industries Ltd.'s shareholder base and identify any potential risks or opportunities. The shareholder base of Sun Pharmaceutical Industries Ltd. is diverse, which is a positive sign for long-term investors.

Sun Pharmaceutical Industries Ltd. Premium Features:

Our website provides premium features tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools can help investors make better investment decisions by providing more detailed insights into the company's financial performance and valuation.

X